Phase 2 Long COVID Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with Long COVID, meaning you have had ongoing symptoms affecting your body for more than 3 months after a COVID-19 infection.
- You have also been diagnosed with POTS (a condition where your heart rate rises unusually fast when you stand up), with symptoms lasting more than 3 months.
- Your POTS diagnosis has been confirmed by a heart rate and blood pressure test done before joining the study.
- If you are between 18 and 21 years old, your heart rate increase when standing must meet slightly higher thresholds to qualify (confirm with trial site).
- Your past COVID-19 infection can be confirmed in several ways — such as a positive PCR or rapid antigen test, a doctor's note, having had typical COVID symptoms, or having been in close contact with a confirmed case at least 3 months ago.
Who may not be able to join:
- You currently have an active COVID-19 infection (within the last 4 weeks).
- You have a moderate or severe condition that weakens your immune system.
- You have a known history of serious heart conditions, such as a heart attack, heart failure, a pacemaker, certain heart rhythm problems, stroke, or a mini-stroke within the last 6 months.
- You have high blood pressure that is not controlled, even with treatment.
- You have Type 1 or Type 2 diabetes.
- You have liver problems shown by abnormal blood test results (confirm with trial site).
- You have reduced kidney function shown by a specific blood test result (confirm with trial site).
- You have anemia (low red blood cell levels shown by a blood test).
- You are currently pregnant or breastfeeding.
- You have a known autoimmune disease, or you are currently using steroids or other immune-related treatments.
- You are unable to give your informed consent to participate.
- You have a known allergy to any component of the study medication.
- You are currently taking certain medications, including specific drugs for memory/nerve conditions (such as pyridostigmine or donepezil), aspirin (or have an aspirin allergy), or a class of antidepressants called MAO inhibitors (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Cyndya Shibao, M.D, Vanderbilt University Medical Center
Phone: 6159702384
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Effect IsoLG-adducts (2-HOBA) measured by levels of monocyte/T cell doublets in LCPOTS.; Changes in Splanchnic venous capacitance before and after 28 days of treatment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.